Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression

K BURNAND, G CLEMENSON, M MORLAND, P E M JARRETT, N L BROWSE

Summary and conclusions
The value of fibrinolytic enhancement with an anabolic steroid (stanozolol) combined with elastic stockings in treating venous lipodermatosclerosis was assessed in a six-month double-blind cross-over trial. Thirty-four legs of 23 patients in whom other treatments had failed were studied. The patients were randomly divided into two groups who were treated with either stanozolol plus elastic stockings or placebo plus elastic stockings for three months, and then vice versa. Treatment with or without stanozolol caused the area of lipodermatosclerosis to decrease, but the rate of healing when patients took stanozolol was double that when they took the placebo, and this was assumed to be biologically important. Stanozolol also reduced the incidence of extravascular fibrin detected in skin biopsy specimens. The elastic stockings with placebo produced significant decreases in leg volume, ankle circumference, and skin thickness.

Stanozolol is valuable in treating intractable lipodermatosclerosis, giving relief of pain and reducing induration, inflammation, tenderness, and pigmentation.

Introduction
We have described the apparent beneficial effect on venous lipodermatosclerosis (liposclerosis; the changes in the skin and subcutaneous changes commonly known as “the postphlebitic leg”) of stimulating blood fibrinolytic activity with the anabolic steroid stanozolol (Stromba). The rationale for this treatment was based on the detection of pericapillary interstitial cuffs of fibrin that, by acting as a diffusion barrier, appeared to be the ultimate cause of venous ulceration.

The results of this pilot study encouraged us to conduct a double-blind cross-over clinical trial to assess the value of stanozolol in the treatment of venous liposclerosis, which is often resistant to other methods of treatment. This trial compared the effect of stanozolol and elastic stockings with the effect of elastic stockings and placebo on the rate of resolution of the area of liposclerosis. It was not a study of the healing of venous ulceration.

Patients and methods

PATIENT SELECTION

In the pilot study1 we selected a group of patients who had been attending our vein clinic for some years and added stanozolol to their treatment, leaving all other treatments unchanged. All these patients had stopped using elastic stockings. In the present trial we wished to study recently referred patients in whom conventional operations had failed. We did not think that it was ethically justifiable to withhold the use of elastic stockings; consequently all patients were prescribed new, properly fitted below-knee Sigvaris elastic stockings, and the trial compared the effect of elastic stockings plus placebo tablets—that is, elastic stockings alone—with the effect of elastic stockings plus stanozolol.

Recently referred patients presenting at the clinic who had had no operations for at least one year and for whom no further operations were contemplated, and who had active liposclerosis but no venous ulceration, were asked to participate in the trial. Informed written consent was obtained from all patients.

PATIENT ASSESSMENT

A full clinical history was recorded, with particular attention being paid to the patient’s age, sex, weight, history of leg disease and deep vein thrombosis, family history, and smoking habits. The state of the leg disease was assessed from the history and the results of the following tests.
Area of liposclerosis—The edge of the liposclerosis was determined by careful inspection and palpation and marked with a fine felt-tip pen. The enclosed area was measured by placing a piece of standard-weight tracing paper over the leg, tracing the marked edge on to the paper, cutting out the enclosed area of paper, weighing it, and converting this result into a measurement of area by using the known weight of 1 cm² of paper. Every area was calculated by the same observer without knowledge of either the shape or size of the area when measured before, or of the form of treatment. The reliability of the method was tested by measuring 10 areas of liposclerosis on two separate occasions, the observer having no knowledge of the size of the first measurement when determining the second. The mean of the first 10 measurements was 73.3 cm² and of the second 76.7 cm², a difference of 4.5 cm². Mean circumferences of the two sets of measurements were 32.3 and 33.6 cm respectively, a difference of 1.3. When individual pairs of measurements were examined the second measurement of area was from −3 cm², to +17 cm², greater than the first (mean ± 7 cm²). The second measurement of circumference was from −7 cm, to +15 cm, greater than the first (mean ± 6.8 cm). This technique of measurement thus had an overall accuracy within the range 10 cm² for both area and circumference, and any change between pairs of measurements or means of groups of measurements over 20 cm² was regarded as significant.

Clinical photographs were taken in black and white, colour, and infrared with the leg in a standard position to provide a permanent record of the changes that occurred during the trial.

Circumference of the leg was measured at a point 10 cm above the medial malleolus.

Leg volume was measured by water displacement to a constant level, 45°C on±0.18 in) above the sole.

Skin thickness was measured on the medial side of the leg, 10.2 cm (±4 in) above the medial malleolus, using soft-tissue radiography. ¹

Skin biopsy specimens for assessing capillary proliferation and extra-vascular fibroblast deposition were taken from a point 7.5 cm above the medial malleolus. The assessor (the late Dr I W Whimster) had no knowledge of the form of treatment.

Foot vein pressures were measured at rest and during maximal heel-raising exercise before and at the end of the trial.

General blood studies such as haemoglobin concentration, packed cell volume, plasma protein concentrations, and liver function tests were performed by the usual pathology services.

Special blood tests—Blood was taken between 0930 and 1030 by clean vein puncture without congestion, in the fasting state, for measurement of plasma protein, cholesterol, and lipoprotein levels and for determination of clotting time and dilute blood clot lysis time (DBCLT). ²

PLAN OF TRIAL

The above tests were performed before the trial began. The patients were then fitted with Sigvaris elastic stockings, which were renewed at any time if they appeared to be getting slack. Randomised allocation cards were used to determine the order of treatment, and each patient was given either stanozolol 5 mg twice daily or placebo twice daily for three months; the treatment was reversed during the second three months. A simple clinical assessment was performed at six weeks, as were blood tests. All the initial tests were repeated at three months, when the drugs were crossed over. The simple clinical assessment and blood studies were repeated at 18 weeks. All tests, and usually the studies of foot vein pressure, were repeated at the end of six months.

Analysis of results—Results were analysed in groups using paired and unpaired Student's t tests.

Results

Out of 23 patients (10 women and 13 men) who entered and completed the trial, nine were given placebo first and 14 stanozolol. This difference occurred because of the method of allocation but does not affect the results because the drugs were crossed over at three months. The mean age of the patients was 57 years (range 38–71). This was also the mean age of both sexes when considered separately. The average weight of the 23 patients was 79.4 kg (175 lb), range 68.0–84.4 kg (150–217 lb). Eight patients were smokers.

Seven patients had a definite history of deep vein thrombosis, 17 a family history of varicose veins, and three a history of intermittent claudication but no symptoms of arterial ischaemia at the time of the trial. All patients had varicose veins, which they had reported been present for a mean of 22 years (range 6–50). The symptoms and signs of liposclerosis (eczema, pigmentation, pain, and induration) had been present for a mean of 11 years (range 2–25). In 12 patients the disease was unilateral and in 11 bilateral. No patients had open ulceration at any time during the trial. Extensive varicose vein surgery such as high ligation, saphenous vein stripping, communicating vein ligation, and various forms of injection sclerotherapy had been performed on all the legs with liposclerosis over many years but not within one year before the trial.

Four of the nine patients who began with placebo and elastic stockings had unilateral disease and five had bilateral disease, giving 14 legs for analysis; and eight of the 14 patients who began with stanozolol and elastic stockings had unilateral disease and six had bilateral disease, giving 20 legs for analysis. Thus 34 areas of liposclerosis were studied during the six-month trial.

LIPOSCLEROSIS

Figure 1 shows the changes in the mean areas of liposclerosis in the two groups. Figure 2 compares these results, indicating the possibility that the response in the second three months might have been affected by the response in the first three months. Figure 3 compares the means of the areas that were healed by the two forms of treatment.

The mean area of healing during treatment with stanozolol and elastic stockings was 155 mm² (SE of mean 40) compared with 78 mm² (SE of mean 15) during treatment with placebo and elastic stockings. An unpaired t test showed that the probability that this was not a chance difference was 90·. This is not usually regarded as a statistically significant difference, but we believe that this difference was biologically important. The beneficial effect of the stanozolol was blurred by using elastic stockings, which were effective in their own right.

The increased rate of healing with stanozolol occurred whether it was given in the first or second three months of treatment (fig 1).
In both groups of patients the area that healed doubled when they were taking stanozolol (173 mm² compared with 83 mm² and 130 mm² compared with 72 mm² respectively). The changes in the areas of liposclerosis for both forms of treatment at three and six months were significant when both groups were considered separately (fig 1) or together (fig 2).

Patients were asked at each visit whether they thought that the pain, heat, colour, and hardness of the liposclerosis had improved over the previous six weeks. After three months' treatment with placebo and elastic stockings six of the nine patients thought that their legs were better. After the second three months, when they took stanozolol, all considered that there had been further improvement. Eleven of the 14 patients who began treatment with stanozolol thought that their legs had improved at the end of three months; but after three months on placebo only nine thought that there had been further improvement. Almost all the patients thus believed that treatment had improved their liposclerosis, but most could not detect any difference between their responses to placebo and stanozolol even though the mean area of healing was greater when they were taking stanozolol.

**LEG DIMENSIONS**

Figure 4 shows the changes in mean leg volume, ankle circumference, and skin thickness. When patients were treated with placebo plus elastic stockings, their leg volumes fell significantly, whereas leg volumes increased (though not significantly) during treatment with stanozolol plus elastic stockings.

Ankle circumference increased significantly in those patients who began treatment with stanozolol plus elastic stockings and decreased significantly when they changed to placebo and elastic stockings. There was a similar, but non-significant, reduction in ankle circumference in the patients who began treatment with placebo plus elastic stockings, but there was no change when this group changed to stanozolol.

The skin 10.2 cm (4 in) above the medial malleolus of the patients who were given stanozolol first became thicker but then showed a significant thinning during treatment with placebo and elastic stockings. The skin thickness of the patients who took placebo first and then stanozolol showed no significant change.

**BLOOD CHANGES**

The haemoglobin and plasma protein concentrations showed no significant changes throughout the trial. The only liver-function test result to change during treatment with stanozolol was serum aspartate transaminase (serum AST; SGOT) activity. In 15 of the 23 patients it did not alter; in five it rose from a mean of 50 units to a mean of 78 units (range 70-90); normal range 25-65); and in three it rose to 115, 125, and 140 units respectively but fell to normal levels within one month of changing to placebo. Three patients showed a slight increase in their serum creatinine concentrations.

Mean plasma fibrinogen concentration fell significantly during treatment with stanozolol plus elastic stockings and rose significantly when stanozolol was stopped (fig 5). The group that took placebo for the first three months showed no change in mean plasma fibrinogen concentration during this time. Their mean plasma fibrinogen concentration fell during the second three months, when they were taking stanozolol, but this fall did not reach significance (P = 0.09).

The mean DBCLT fell significantly for the first three months in the patients who began treatment with stanozolol and rose significantly during this time in the patients who began treatment with placebo. The other changes in DBCLT (fig 5) were in the expected direction but did not achieve significance. This was almost certainly because of the wide natural variations in DBCLT and the small numbers of patients studied.

**SKIN HISTOLOGY**

The biopsy specimens were studied to assess the number of skin capillaries and the incidence of extravascular fibrin. Biopsies were performed before treatment and at three and six months on 34 legs.

Capillary proliferation was divided into four grades of severity—normal, mild, moderate, and severe—and converted into numerical scores (0, 1, 2, and 3 respectively). The mean capillary proliferation scores for each group of patients whether receiving stanozolol or placebo decreased steadily throughout the trial (fig 6). Over the whole six months the mean score of all patients fell from 2.7 to 2.2.
in some patients there is extensive irreparable deep vein damage and operations are ineffective.\footnote{Our studies suggest that venous liposclerosis, and eventually venous ulceration, are caused by deposition of an impermeable fibrin cuff around the dermal capillaries, caused by prolonged venous hypertension and exacerbated by a deficiency of blood and tissue fibrinolytic activity.\footnote{As we had to treat a group of patients in whom conventional treatment had failed we thought it reasonable to assess the effect of stimulating the fibrinolytic system with stanozolol. A pilot study\textsuperscript{6} indicated that this would be worth while, and we set up a double-blind cross-over trial to test this drug. The major problem was assessing the liposclerosis. Measuring an indurated tender area of skin and subcutaneous tissue is difficult. We chose our method of measurement because it was simple, direct, and reproducible to within \(10\%\). Other methods of assessing healing, such as percentage change or those entailing calculations of area and perimeter length, appeared to offer no advantages.}
}

To gain as much information as possible about the leg we measured leg circumference, leg volume, skin thickness, and foot vein pressure and assessed skin histology (for capillary proliferation and extravascular fibrin). These additional measurements were particularly relevant to the mechanical effects of the elastic stockings, which we felt ethically obliged to investigate in our treatment regimen.

Stanozolol prolonged the mean DBCT and reduced mean plasma fibrinogen concentrations; blood fibrinolysis was, therefore, enhanced. This confirms the results of other studies of stanozolol.\footnote{Unfortunately stanozolol takes four weeks to produce this effect, and after stopping treatment the effect takes four weeks to wear off. This makes interpretation of the results in the second three-month period for those who took stanozolol in the first three months difficult, because for at least one month of their treatment with placebo their blood fibrinolysis was still partially enhanced. Without this “hangover” effect some of the results that only just reached significance might have been more significant.}

Both placebo plus elastic stockings and stanozolol plus elastic stockings produced a highly significant reduction in the mean area of liposclerosis (\(P < 0.01\)). The mean rate of healing was twice as great when the patients were taking stanozolol, but the statistical probability that this difference was caused by the drug was only \(90\%\). Nevertheless, we believe that this is a biologically important difference because of the other changes that occurred when the patients took stanozolol such as rapid alleviation of pain and tenderness, and particularly the loss of skin pigmentation, which did not occur in the period of treatment with placebo. These differences were impossible to quantify but, since the mean healing rate doubled (figs 1, 2, and 3), we are certain that stanozolol had a real, significant, and independent effect, which was also apparent in our pilot study in which elastic stockings were not used.\footnote{Our present study did not include a group of subjects who were not treated because all the patients had been specially referred to our clinic from other centres because their liposclerosis was deteriorating or had failed to respond to other treatment. Spontaneous improvement was, therefore, unlikely, and we thought that a “non-treatment” group was unjustifiable.}

By causing minor fluid retention stanozolol opposed the effect of the elastic stockings in reducing mean leg volume and circumference but not to the extent that the mean leg volume increased. Placebo plus elastic stockings—that is, elastic stockings alone—caused a significant reduction in mean leg volume. All biopsies showed some capillary proliferation. This was not altered by stanozolol but did reduce over the six months of the trial, presumably as a result of compression caused by the stockings. All pretreatment biopsy specimens contained extravascular fibrin. Placebo and elastic stockings given for the first three months of the trial did not alter the quantity of fibrin in the specimens. Stanozolol plus elastic stockings reduced the number of specimens containing fibrin by about \(20\%\), in both
groups. There was also a reduction in the number of biopsy specimens containing fibrin taken from those patients treated with placebo plus elastic stockings for the second three months of the trial, but whether this was a hangover effect from the previous three months of taking stanozolol or an effect caused by the elastic stockings is impossible to say. It is unlikely to have been caused by the stockings because it did not occur in those who began treatment with placebo and stockings.

The mean exercising foot vein pressures were unaltered by the trial. This confirmed that the treatment caused no fundamental change in the efficiency of the calf muscle pump, though pump function was certainly changed while the elastic stockings were being worn.\(^1\)

The side effects of treatment were slight and did not cause anyone to stop treatment. Liver-function test abnormalities were minor and resolved spontaneously.

All but one patient believed that their legs had improved but were unable to differentiate between the effect of placebo and that of stanozolol except for the effect on pain. The burning discomfort that some patients suffered in the area of liposclerosis ceased within three to four weeks after beginning stanozolol. All patients wanted to continue treatment with stanozolol after the trial had ended. The long-term results have been encouraging and will be the subject of a further report. In almost every patient the induration has disappeared after six to nine months of treatment, and in many the brown pigmentation has also regressed. We have stopped giving stanozolol after 12 months of treatment, and so far the legs have remained healthy with the use of good elastic stockings.

Stanozolol is a useful addition to the treatment of venous liposclerosis, but we advise that it is used only in intractable cases in which other methods of treatment have failed. Stanozolol takes at least three months to produce a worthwhile response and nine to 12 months to achieve its maximum effect. During this time the patient should be observed carefully for evidence of excessive water retention or masculinisation, and liver-function tests and measurements of plasma fibrinogen concentrations conducted regularly. Stanozolol may be assumed to be enhancing fibrinolysis if the plasma fibrinogen concentration falls, but administration should be stopped if AST activity rises above 120 units.

The clinical response of liposclerosis to fibrinolytic enhancement and the histological evidence of a reduction in the quantity of extravascular fibrin in the skin of some patients after only three months of treatment with stanozolol support our hypotheses on the aetiology of venous ulceration. The results of this trial have encouraged us to look for other drugs that are more effective long-term stimulators of blood, interstitial fluid, and tissue fibrinolysis.

We are grateful to Winthrop-Sterling and the trustees of St Thomas's Hospital Endowment Fund for financial help.

Requests for reprints should be addressed to Professor N L Browse.

References


(Accepted 17 October 1979)